leisure time -WSS

leisure time

author：explore 2025-09-04 17:33:06 - browse：2

AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it was spun off from the device maker Abbott Laboratories in 2013, will step down in July. Gonzalez had previously said he would depart when AbbVie had a plan in place to move on from its best-selling drug, Humira, which is now facing competition from cheaper biosimilars.

He will be replaced by Chief Operating Officer Robert Michael, who, like Gonzalez, is a longtime AbbVie executive. Gonzalez, 70, will become executive chairman of the board of directors.

Gonzalez should be a sobering reminder to the drug industry’s critics of how resilient a CEO’s reputation can be. Because while he has been a subject of nearly constant criticism for AbbVie’s handling of Humira and the patents protecting it, investors are likely to remember him fondly.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Kristina Burow of ARCH Venture Partners shares her next big bets STAT

leisure time

hotspot

WSS

FogPharma raises $145 million in rare Series E round

Clinical trials giant ICON acquires HumanFirst

Pfizer highlights cancer drugs it thinks could reignite investor interest

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Obesity now affects over 1 billion people worldwide, study finds

entertainment

leisure time

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Study finds gene variants tied to breast cancer risk in Black women

Sports medicine is finally prioritizing gender equality

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

In Memoriam: Notable people who died in 2023

ASCO eve: Let’s set the table for this year's meeting

In age of alternative facts, a scholarly course on calling out crap

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

As demand for Covid shots wanes, Moderna seeks its next success

FDA poised to publish guidelines for clinical trial diversity

entertainment

AstraZeneca loses challenge to Medicare drug price negotiation

Liver decline slowed by off

ALS groups 'won't be played again' by the FDA, drug sponsors

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

In search for therapies for solid tumors, companies turn to claudin

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

focus

leisure time

hotspot

hotspot